Lead Discovery Center GmbH

Lead Discovery Center GmbH (LDC) is a prominent player in the pharmaceutical research sector, established in 2008. The company specializes in transforming early-stage projects into leads with initial proof-of-concept in animals, focusing on small molecules. LDC collaborates closely with the Max Planck Society and a range of high-profile partners from academia and industry to develop a strong portfolio of small molecule leads with exceptional medical and commercial potential. The company's dedicated team consists of industry-trained experts with extensive experience in project management and drug discovery, offering core expertise in Automation & Screening, Cellular Biology, Pharmacology, Medicinal Chemistry, and therapeutic Antibody Discovery. LDC's unique approach capitalizes on the potential of basic research for the discovery of new therapies for diseases with high medical need. LDC has formed alliances with a roster of industry leaders including AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi-Sankyo, Qurient, Johnson & Johnson Innovation, Roche, and Sotio, as well as leading translational drug discovery centers globally. The company is headquartered in Germany and operates within the Health Care and Pharmaceutical industries. The seamless integration of academic collaboration and industry partnerships, coupled with LDC's expertise and focus on diseases with high medical need, positions the company as an influential force in the pharmaceutical research landscape. With a track record of successful partnerships and a commitment to innovative drug discovery, LDC presents an exciting opportunity for potential investment within the health and pharmaceutical sectors.